MapLight Therapeutics Q3 net loss widens 75% to $51.62 million
MPLT•MapLight Therapeutics’ third-quarter 2026 net loss widened 75% year over year to $51.62 million. The company reported $463.4 million in cash, cash equivalents and investments, which it expects to fund operations through 2028.
1. Quarterly results and trials
MapLight Therapeutics’ third-quarter 2026 net loss widened 75% year over year to $51.62 million. Research and development expenses rose 63% to $44.21 million, while general and administrative expenses more than doubled to $11.14 million. Cash, cash equivalents and investments totaled $463.4 million at September 30, which the company expects to fund operations through 2028. Start-up activities began for the planned Phase 3 ZEPHYR-2 schizophrenia trial of ML-007C-MA, with topline results expected in 2028; enrollment continues in the Phase 2 VISTA Alzheimer’s disease psychosis trial, with topline results expected in the second half of 2027.




